Home /

Solutions /

Therapeutics

Accelerate Therapeutic Lead Discovery With DeepMirror Bio

DeepMirror Bio uses known molecule - target interactions and molecular properties to estimate unknown ones and suggest optimal leads to synthesise. The technology has been developed for RNA, Small Molecules, and Protein (e.g. peptides and antibodies). We also offer DeepMirror Image: a micro service that is used to build automated image analysis pipelines for Target Discovery and preclinical work.

Small Molecules
Oligos
Antibodies & Peptides

Therapeutics Pipeline

Target
Discovery
Hit to Lead
Lead
Optimisation
Preclinical
Studies
Clinical
Studies
Approval

DeepMirror Digital Workflows

Small Molecule Assays

Suitable for:

Hit to Lead

Lead Optimisation

In Small Molecule Assays, researchers measure molecule properties (such as ADME and target binding) to find optimal candidates to move into the clinic. Using DeepMirror Bio, they can identify the most relevant candidates to synthesise and de-risk drug discovery.

RNA Assays

Suitable for:

Hit to Lead

Lead Optimisation

In RNA assays, researchers measure properties of RNA (such as mRNA or siRNA) to find optimal sequences that can have therapeutic value. Using DeepMirror Bio, they can identify the most relevant candidates to synthesise and de-risk drug discovery.

Protein Assays

Suitable for:

Hit to Lead

Lead Optimisation

In protein assays, researchers measure properties of protein such as peptides and antibodies to find new medicines. Using DeepMirror Bio, they predict protein properties from a few measured datapoints to identify optimal amino acid sequences with high therapeutic value.

High Content Imaging

Suitable for:

Target Discovery

Hit to Lead

Preclinical studies

In High Content Imaging researchers use large amounts of microscopy data e.g. to reach conclusions about the efficacy of a drug or the diagnosis of a disease. Using DeepMirror Image, we can build automated image analysis pipelines 5x faster than other platforms due to less data requirements.